Cramer’s lightning round: Marvell Technology and Bausch Health are buys

Bausch Health: “We wanted to buy more today, but we ran out of time. This thing is being put on sale. There are shorts taking it all the way down. It is quite ridiculous. I wanted to be able to buy a huge slug of it today, so that’s how I feel for the [Charitable Trust].”

Accenture: “They crushed that stock. The business is fantastic. They had a great quarter. I’m saying to people [buy, buy, buy].”

Celularity: “That’s one of the higher risk stocks out there. The way I’d look at it is, be prepared to lose everything but otherwise make a lot of money if it works out.”

Manulife: “They take on too much risk, Manulife. I’m not there for the 5% [dividend yield]. I don’t need it. Too much risk in the common stock.”

Marvell Technology: “You should [keep buying more of it]. This company has two businesses: high-performance computing and 5G. We know those are the two strongest areas. It has no PC business. It has no gaming. Marvell is a stock that we’ve been buying, buying, buying for the Charitable Trust, and I think you should, too.”

Iron Mountain: “I like Iron Mountain. Good yield, very consistent business. [Buy, buy, buy].”

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com